An unprecedented trial conducted by a U.S. biotechnology company is attempting to resurrect the clinically dead.
Bioquark Inc. has been granted permission to recruit 20 patients who have been declared clinically dead due to traumatic brain injury. The researchers will try to bring certain parts of the central nervous system back to life through a combination of innovative therapies, including injecting peptides into the spinal cord daily, injecting stem cells into the brain twice a week, transcranial laser therapy and nerve stimulation techniques.
